MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

National Grid has an enviable geographic footprint. The UK has the most favorable regulatory environment for energy networks in Western Europe, while US returns are higher than in most European ...